Daiichi Pharma to Return Commercial Rights for Anti-Platelet Agent to Sanofi

摘要

Sanofi-aventis and Daiichi Pharmaceutical have reached an agreement on the latter's transfer of all commercial rights for Plavix (clopidogrel Sulfate),an antiplatelet agent,to Sanofi-aventis Japan.